Related Experiment Video
Updated: Feb 19, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.3K
Relevance of CYP2C9 Function in Valproate Therapy
Katalin Monostory1, Andrea Nagy2, Katalin Tóth1
1Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Current Neuropharmacology
|November 10, 2017
Summary
Pediatric valproate metabolism is primarily driven by CYP2C9, with genetic variations impacting drug safety. Tailoring therapy to a child's CYP2C9 status is crucial for preventing adverse reactions.
Area of Science:
- Pharmacogenomics
- Pediatric Pharmacology
- Drug Metabolism
Background:
- Genetic variations in drug-metabolizing enzymes influence drug pharmacokinetics, efficacy, and toxicity.
- Non-genetic factors like age and disease can alter enzyme activity, leading to genotype-phenotype mismatch.
- Pediatric patients are uniquely susceptible to valproate-induced injury due to age-related metabolic differences.
Purpose of the Study:
- To investigate the role of CYP2C9 in pediatric valproate metabolism.
- To explore the impact of genetic and non-genetic factors on valproate pharmacokinetics in children.
- To propose a strategy for optimizing valproate therapy in pediatric patients based on CYP2C9 status.
Main Methods:
- Analysis of CYP2C9-mediated valproate oxidation as a primary metabolic pathway in children.
- Evaluation of loss-of-function alleles (CYP2C9*2, CYP2C9*3) and their effect on valproate metabolism.
- Assessment of phenoconversion, where genotype does not accurately predict metabolic phenotype.
Main Results:
- CYP2C9 is the principal route for valproate metabolism in children, unlike in adults.
- Loss-of-function CYP2C9 alleles significantly reduce valproate metabolism in pediatric patients.
- Even individuals with the wild-type CYP2C9 genotype can exhibit reduced metabolic capacity due to phenoconversion.
Conclusions:
- A novel therapeutic strategy for valproate, adjusted for CYP2C9 status (genotype and expression), is recommended for pediatric use.
- Early assessment of pediatric patients' CYP2C9 status can optimize valproate dosing.
- Optimized dosing based on CYP2C9 status can prevent misdosing-induced adverse reactions and enhance anticonvulsant therapy safety in children.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
719
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
719
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
01:27Pharmacogenetics of Drug Metabolism: Overview
23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
01:25Pharmacokinetics: Drug–Drug Interactions
497
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
497
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
775
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
775